Akihiko Yamamoto

Company: Eisai Co., Ltd.

Job title: Senior Director

Seminars:

Delivery of A BET Protein Degrader via A CEACAM6-Targeted ADC – Highlighting Preclinical Efficacy Against Pancreatic Cancer 2:30 pm

Exploring the properties of BET protein degrader as a payload and inducing the bystander effect Examining the pharmacological profile of our CEACAM6-EBET ADC Reviewing data portraying cancer-cell-killing activity and stromal modulation activity in PDX modelsRead more

day: Day One